Phosphagen. Share Discussion Threads

[hopeless698] 21/6/2007 07:28

RNS Today - Trans Dermal Breakthrough!

[ladybird1] 20/6/2007 07:58

Nothing supernatural, LGW. The summary page showed a posting on 19/06. The only one actually on the board was from 13/06. QED.

[lgw] 19/6/2007 22:39

how did you do that ladybird, surely you could not have known post was missing until you posted 525.

[ladybird1] 19/6/2007 09:27

Post 524 seems to have got stuck in the system somewhere & is not showing. Might whoever posted it please resend?

[rambutan2] 13/6/2007 23:15

didn't take much prompting - 100k buy at 12.5p

[flintsurfer] 13/6/2007 20:40

little bit of movement...

[rambutan2] 05/6/2007 00:14

yes, A$5.3m from recent grants isn't to be sneezed at and has most likely saved us from some dilution - if compare and contrast to recentish placing you could say ththe grants are worth at least 17m share dilution...

22 December 2006
Notice under Australian Stock Exchange Section 708A Corporations Act 2001 (Cth) (Act)
Melbourne, Australia, 22 December 2006, Phosphagenics (AIM:PSG, ASX:POH):
Further to the Company's announcement on 13 December 2006 advising of the
completion of the placement of 33,333,333 new ordinary fully paid shares to
overseas and domestic institutional and sophisticated investors at an issue
price equivalent to A$0.30 a share for a total raising of A$10,000,000.00. The
Company now confirms that the shares have been issued to the placees and were
granted quotation on the official lists of the Exchange under the security code
of: POH, as of Friday 15 December 2006.

[lgw] 04/6/2007 13:46

This is the second grant in a short space of time, can't complain either about free money.

[spaceparallax] 04/6/2007 09:52

Can't complain, it is additional money for the trials.

[hopeless698] 04/6/2007 08:58

news just come in re. been offered a grant, quite dissapointing! Thought it would be 3 million

[lgw] 29/5/2007 04:33

Interesting article Rambutan2 ,could be L'oreal or P&G.
At least we know it is a MAJOR cosmetic company.
This is the PSG product used in anti-aging creams etc the article above mentions the aging world population and L'Oreal 's desire to increase products targeting this market.You can see below how many applications use Vital ET, my bathroom cupboard is full of them.

VITAL ET® - Phosphorylated Tocopheryl
INCI Name
Disodium Lauriminodipropionate Tocopheryl Phosphates
DESCRIPTION
Appearance: Tan Emulsion
Solids: 35-40% in Water
pH: 5-7
Recommended Use Levels:
0.3%-3.0% Active
PROPERTIES
Vital ET® is a new and unique bio-functional complex of tocopherol phosphate that can reduce the appearance of redness and swelling on skin. Vital ET® can be used in products targeting the effects of aging and environmental stress. It is also excellent in shaving formulations because of its calming effect on the skin, anti-redness benefits, and excellent skin lubricity.
KEY BENEFITS
- Effective at reducing the appearance of redness and swelling
- Excellent skin lubricity
- Elegant skin feel
- Complementary benefits in acne related products
- Compatible with a broad range of raw materials
- Easy to formulate into oil and water based systems
APPLICATIONS
Sun Care: Sunscreens and After-Sun Products
Skin Care: Daily Use Body Creams, Anti-Acne, Shaving Products, Diaper Rash Creams and Antiperspirants
Color Cosmetics:
Foundations and Concealers

[rambutan2] 27/5/2007 22:05

from the agm statement: "Additionally, during 2006 we signed an alliance with a major cosmetic company that unfortunately cannot be named as yet."

from the sunday times today - well, it could be?
"But there is also a lot that could turn sour. L'Oréal's ownership structure makes some uneasy. The Swiss multinational Nestlé has 28% of the company – an interest it has held since 1974. Another 29% is held by Liliane Bettencourt, the 84-year-old daughter of L'Oréal's founder, Eugène Schueller. That stake alone makes her the richest woman in the world. But will her family keep the stake? And what are Nestlé's intentions?"

[lgw] 25/5/2007 22:38

Psg will improve the lives of many ill people.
Whilst patience is necessary I am convinced that PSG or parts of the company will be taken out some time within the next 18-24 months. Those of us willing to hang on or add to our holding (as I intend to do) will be very well rewarded.
Cheap as chips for those with a long term prospective 60p-70p 18mths imo. no advice intended.

[rambutan2] 25/5/2007 10:40

good agm statement...

[spaceparallax] 24/5/2007 13:21

The march towards the prize continues.

[suesean1] 17/5/2007 15:30

Can shares mag be obtained from a newsagents?

[suesean1] 17/5/2007 15:27

sean.

Space

[spaceparallax] 17/5/2007 15:25

Susan,

Thanks for the tip, I don't subscribe to Shares, but am happy to provide info from IC and GCI.

[suesean1] 17/5/2007 11:18

Anyone subscribe to shares mag?

SHARES MAGAZINE
Set to Soar (Off the radar but not for long, the market's undiscovered gems):
*Amiad Filtration Systems (AFS.L) - Block Shield (BLS.L) - Brulines (BRU.L) - Business Control Solutions (BCT.L) - Charteris (CAE.L) - Dawson Holdings (DWN.L) - Findel (FDL.L) - Granby Oil & Gas (GOIL.L) - Hichens Harrison (HICH.L) - Highland Timber (HTB.L) - Immupharma (IMM.L) - Jarvis (JRVS.L) - Phosphagnics (PSG.L) - Phytopharm (PYM.L) - Portrait Software (PST.L) - Prince Catering (PRNC.L) - Reflec (REF.L) - Robinson (RBN.L) - Straight (STT.L) - TripleArc (TPA.L).

[spaceparallax] 15/5/2007 10:01

Drifting, I'm rather surprised after the recent issue.

[spaceparallax] 03/5/2007 09:24

Nice little bonus.

[basketbob] 03/5/2007 09:22

Phosphagenics Limited
03 May 2007

Phosphagenics Limited



AusIndustry offers Phosphagenics a Pharmaceuticals Partnerships Program (P3)
grant of $3.2 million



03 May 2007



Melbourne, Australia, 03 May 2007: The Industry Minister, Hon Ian Macfarlane,
announced today that Vital Health Sciences Pty Ltd, a wholly-owned subsidiary of
Phosphagenics Limited (ASX: POH) (AIM: PSG) (ADR/OTC: PPGNY), has been offered a
research grant under the AusIndustry Pharmaceuticals Partnerships Program (P3)
of up to $3.2 million.



P3 is a competitive government grant program aimed at increasing the amount of
high quality pharmaceutical R&D activity in Australia. The P3 grant entitles
Phosphagenics to funding of up to $3.2 million over two years starting from 01
July 2007 to support a number of its drug-development projects, dependent on the
company meeting forecast R&D expenditure for the period.



The funding will be used to further develop Phosphagenics' R&D portfolio,
including the following:



• pre-clinical and clinical development of its TPM transdermal delivery
technology and oral drug delivery technology for the treatment of diabetes,
chronic pain management and other markets; and



• pre-clinical and clinical development of its lead compounds for the
treatment of atherosclerosis/metabolic syndrome (APA-01) and the treatment of
cancer (GTP-0805).





Mr Harry Rosen, President and CEO of Phosphagenics, said 'Phosphagenics patented
technologies are world class and address areas of medical need such as diabetes,
metabolic syndrome and chronic pain. The support of the government and this
grant will not only help Phosphagenics meet its key milestones, but also
provides support for our local scientists, researchers and developers.'



APPENDIX AND NOTES TO EDITORS



About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company
focused on the discovery of new and cost effective ways to enhance the
bioavailability, activity, safety and delivery of proven pharmaceutical and
nutraceutical products.



Phosphagenics' core technology is built around the science and application of
phosphorylation, a process where the addition of a phosphate group has been
found to enhance the bioavailability, activity and safety of existing
pharmaceuticals and nutraceuticals, as well as to assist in the production of
drug delivery platforms.



Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the
London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1
program has been established in the US with the Bank of New York (PPGNY) for US
investors to trade in Phosphagenics' stock on the 'over-the-counter' market.



For more information, please visit Phosphagenics' web site at

www.phosphagenics.com




Company Contact Details: US Investor and Media Contacts:
Dr Esra Ogru Mr Brian Ritchie
Phosphagenics Limited Financial Dynamics
Executive Vice President Research & Development [phone]
[phone]

Mr Harry Rosen
Phosphagenics Limited
Managing Director
[phone]






Safe Harbor Statement

This press release contains forward-looking statements based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialise, actual results could vary materially
from the Phosphagenics' expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic conditions, such
as interest rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations.






This information is provided by RNS
The company news service from the London Stock Exchange
MSCGCGDUGBGGGRX